EML4-ALK biology and drug resistance in Non-Small Cell Lung Cancer: a new phase of discoveries.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13446
Abstract: Anaplastic lymphoma kinase (ALK) can be driven to oncogenic activity by different types of mutational events such as point‐mutations, for example F1174L in neuroblastoma, and gene fusions, for example with echinoderm microtubule‐associated protein‐like 4 (EML4)… read more here.
Keywords: non small; small cell; biology; eml4 alk ... See more keywords
Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib
Sign Up to like & getrecommendations! Published in 2023 at "ChemBioChem"
DOI: 10.1002/cbic.202200766
Abstract: Metastasis poses a major challenge in cancer management, including EML4‐ALK‐rearranged non‐small cell lung cancer (NSCLC). As cell migration is a critical step during metastasis, we assessed the anti‐migratory activities of several clinical ALK inhibitors in… read more here.
Keywords: brigatinib; cell; eml4 alk; alk ... See more keywords
Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement
Sign Up to like & getrecommendations! Published in 2021 at "Virchows Archiv"
DOI: 10.1007/s00428-021-03092-8
Abstract: ALK-positive histiocytosis (APH) is a newly defined entity with specific histological features and a highly recurrent KIF5B-ALK gene fusion. APH is characterized by clonal proliferation of histiocytes and can present as either systemic or localized.… read more here.
Keywords: alk; alk rearrangement; alk positive; positive histiocytosis ... See more keywords
ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-020-03166-1
Abstract: Purpose IHC, FISH, and NGS are common methods of ALK evaluation in NSCLC. The purpose of this study was to investigate whether ALK false positives or false negatives occurred more often in daily routines. An… read more here.
Keywords: alk fusion; alk; alk ihc; cancer ... See more keywords
The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-021-03546-1
Abstract: Anaplastic lymphoma kinase (ALK) gene rearrangement exists in approximately 3–7% of non-small cell lung cancer (NSCLC) and more than 15% split or isolated red signals among 50 tumor nuclei scored in the FISH analysis defines… read more here.
Keywords: alk; alk rearrangement; break apart; alk positive ... See more keywords
Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.09.012
Abstract: OBJECTIVES The molecular profiles and prognosis of anaplastic lymphoma kinase (ALK) fusion and resectable non-small cell lung cancer (NSCLC) remain unclear. This study aimed to explore the distribution of ALK fusion variants and prognostic factors… read more here.
Keywords: alk fusion; alk; fusion variants; lung cancer ... See more keywords
Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.10.015
Abstract: OBJECTIVES The echinoderm microtubule-associated protein-like 4 gene (EML4) and anaplastic lymphoma kinase gene (ALK) fusion is the most common ALK rearrangements in non-small cell lung cancer (NSCLC). Herein, we firstly report that coexistence of a… read more here.
Keywords: alk; nbea alk; alk eml4; fusion ... See more keywords
Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01864
Abstract: Heterobifunctional degraders, known as proteolysis targeting chimeras (PROTACs), theoretically possess a catalytic mode-of-action, yet few studies have either confirmed or exploited this potential advantage of event-driven pharmacology. Degraders of oncogenic EML4-ALK fusions were developed by… read more here.
Keywords: pharmacology; site mutations; catalytic degraders; eml4 alk ... See more keywords
Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.9b00378
Abstract: We report on the synergistic effect of PI3K inhibition with ALK inhibition for the possible treatment of EML4-ALK positive lung cancer. We have brought together ceritinib (ALK inhibitor) and pictilisib (PI3K inhibitor) into a single… read more here.
Keywords: positive lung; alk; alk positive; lung cancer ... See more keywords
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdw693
Abstract: Background Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the standard of care in advanced ALK-rearranged non-small cell lung cancer (NSCLC), but the treatment outcomes and duration of response vary widely. Echinoderm microtubule-associated protein-like… read more here.
Keywords: alk inhibitors; alk; fusion variants; advanced alk ... See more keywords
EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaa156
Abstract: Ovarian cancer is prone to recurrence and chemotherapy resistance. Ovarian tumours of some patients have been positive for anaplastic lymphoma kinase fusion gene expression (ALK+). Preclinical studies indicate that anaplastic lymphoma kinase inhibitor can suppress… read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; ovarian cancer; cancer ... See more keywords